+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metastases



The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metastases



Frontiers in Oncology 4: 151



Image guidance allows delivery of very high doses of radiation over a few fractions, known as stereotactic ablative radiotherapy (SABR). This treatment is associated with excellent outcome for early stage non-small cell lung cancer and metastases to the lungs. In the delivery of SABR, central location constantly poses a challenge due to the difficulty of adequately sparing critical thoracic structures that are immediately adjacent to the tumor if an ablative dose of radiation is to be delivered to the tumor target. As of current, various respiratory motion management and image guidance strategies can be used to ensure accurate tumor target localization prior and/or during daily treatment, which allows for maximal and safe reduction of set up margins. The incorporation of both may lead to the most optimal normal tissue sparing and the most accurate SABR delivery. Here, the clinical outcome, treatment related toxicities, and the pertinent respiratory motion management/image guidance strategies reported in the current literature on SABR for central lung tumors are reviewed.

(PDF emailed within 0-6 h: $19.90)

Accession: 056438311

Download citation: RISBibTeXText

PMID: 25009800

DOI: 10.3389/fonc.2014.00151


Related references

Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non‒small-cell lung cancer or lung metastases. International Journal of Radiation Oncology, Biology, Physics 81(3): 856-862, 2011

Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". International Journal of Radiation Oncology, Biology, Physics 88(5): 1120-1128, 2014

Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. Journal of Thoracic Oncology 10(4): 577-585, 2015

Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry. Radiation Oncology 10: 113, 2016

Stereotactic ablative radiation therapy for centrally located recurrences of non-small cell lung cancer: in regard to Chang et al. International Journal of Radiation Oncology, Biology, Physics 89(5): 1141-1142, 2014

A moving target: Image guidance for stereotactic body radiation therapy for early-stage non-small cell lung cancer. Practical Radiation Oncology 3(4): 307-315, 2014

Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1). International Journal of Clinical Oncology 22(5): 849-856, 2017

Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 72(4): 967-971, 2008

Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future?. Annals of Translational Medicine 3(2): 25, 2015

Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics 98(4): 900-907, 2017

Risks of Stereotactic Ablative Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer With Co-Existing Interstitial Lung Disease: A Systematic Review of Literature. International Journal of Radiation Oncology*biology*physics 96(2): E450-E451, 2016

Analysis of Circulating Tumor Cells in Early Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology*biology*physics 87(2): S200-S201, 2013

Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 80(4): 1015-1022, 2011

Clinical Outcome and Toxicity in Central Located Stage I or Isolated Recurrent Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology*biology*physics 87(2): S514-S515, 2013

Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Journal of Thoracic Oncology 6(12): 2036-2043, 2012